Further Assurance That PCSK9 Inhibitor Doesn't Hurt Cognition

]]>(MedPage Today) -- There was no trade-off of impaired cognition when evolocumab (Repatha) was added to statin therapy for LDL cholesterol lowering, according to patient-reported outcomes from the FOURIER trial.Similar proportions of patients...